CareDx, Inc. (CDNA) News
Filter CDNA News Items
CDNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDNA News Highlights
- For CDNA, its 30 day story count is now at 2.
- Over the past 5 days, the trend for CDNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CDNA News From Around the Web
Below are the latest news stories about CAREDX INC that investors may wish to consider to help them evaluate CDNA as an investment opportunity.
CareDx To Present at the 2023 Cantor Global Healthcare ConferenceBRISBANE, Calif., September 19, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference. |
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023BRISBANE, Calif., September 14, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece. |
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment ConferenceBRISBANE, Calif., August 31, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference. |
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient CareBRISBANE, Calif., August 17, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas. |
Redfin upgraded, CSSE downgraded: Wall Street's top analyst callsRedfin upgraded, CSSE downgraded: Wall Street's top analyst calls |
CareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 13% this week, taking three-year losses to 73%While not a mind-blowing move, it is good to see that the CareDx, Inc ( NASDAQ:CDNA ) share price has gained 20% in the... |
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft RejectionBRISBANE, Calif., August 11, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage Determination (LCD) MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure®, AlloMap® and HeartCare. |
Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key MetricsAlthough the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
CareDx (CDNA) Reports Q2 Loss, Tops Revenue EstimatesCareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
CareDx Reports Second Quarter 2023 ResultsBRISBANE, Calif., August 08, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023. |